



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

June 20, 2019

Daniel E. Greenleaf
Chief Executive Officer
BioScrip, Inc.
1600 Broadway
Suite 700
Denver, CO 80202

Re: BioScrip, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 30, 2019
File No. 001-11993

Dear Mr. Greenleaf:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Beverages, Apparel and
Mining